# September 22, 2026 — scheduled research update (retry)

[Home](../README.md) · [Latest](../LATEST.md) · [Calendar](../MILESTONES.md)

The morning attempt stopped before completion; this evening retry resumes that check. Research through September 22; final verification UTC 2026-09-23T04:17:35Z. Searched from the last successful checks with a seven-day overlap, prioritizing September 18–22. Older additions retain original dates and baseline labels.

46 deduplicated sourced entries, three new attributed informal signals, and 28 focused topic checks. Coverage remains partial; successful-check timestamps are preserved where gaps remain. This is not an exhaustive review or an all-topic no-news conclusion.

## Meaningful findings

- **2026-09-22 — Galleri FDA briefing package and exact voting questions reviewed.** Regulator briefing; verified September 22, original posting date not specified. [Galleri and organ-specific cancer screening](../topics/02_galleri.md#programs-and-next-milestones).
- **2026-09-22 — VK2735 reports results for less frequent maintenance dosing.** Sponsor topline announcement. [GLP-1 and related metabolic therapies](../topics/03_glp1.md#programs-and-next-milestones).
- **2026-09-22 — SUPREME-01 registry now confirms recruitment and revises timing.** Trial-registry update. [Localized fat removal](../topics/06_localized_fat.md#programs-and-next-milestones).
- **2026-09-22 — Vitiligo presentations added to the September 30 calendar.** sponsor conference schedule; no new numerical efficacy result. [Pigmentation and uneven skin tone](../topics/23_pigmentation.md#programs-and-next-milestones).
- **2026-09-22 — NHS-Galleri peer-reviewed report quantifies performance across three screening rounds.** Peer-reviewed descriptive secondary-endpoint analysis within randomized trial. [Galleri and organ-specific cancer screening](../topics/02_galleri.md#programs-and-next-milestones).
- **2026-09-22 — PATHFINDER 2 peer-reviewed publication clarifies denominators and the locked safety dataset.** Peer-reviewed prospective single-arm interventional study. [Galleri and organ-specific cancer screening](../topics/02_galleri.md#programs-and-next-milestones).
- **2026-09-21 — INTerpath-001 detailed phase 3 results scheduled for October 24.** Sponsor conference announcement. [Cancer treatment, vaccines and recurrence prevention](../topics/14_cancer_vaccines.md#programs-and-next-milestones).
- **2026-09-21 — VNX-101 reports responses in three selected leukemia patients.** Sponsor preliminary phase 1/2 report. [Cancer treatment, vaccines and recurrence prevention](../topics/14_cancer_vaccines.md#programs-and-next-milestones).
- **2026-09-21 — ARIKAYCE broader-use application gets priority review.** Sponsor-reported FDA filing action. [Infectious-disease prevention and treatment](../topics/27_infectious_disease.md#programs-and-next-milestones).
- **2026-09-21 — Lower-dose CagriSema reports head-to-head diabetes results.** Sponsor topline announcement. [GLP-1 and related metabolic therapies](../topics/03_glp1.md#programs-and-next-milestones).
- **2026-09-21 — REDEFINE 9 reports weight loss with lower-dose CagriSema.** Sponsor topline announcement. [GLP-1 and related metabolic therapies](../topics/03_glp1.md#programs-and-next-milestones).
- **2026-09-21 — CagriSema reports a Phase 2 painful-neuropathy signal.** Sponsor topline announcement. [Non-opioid acute and chronic pain therapies](../topics/16_pain.md#programs-and-next-milestones).
- **2026-09-21 — CBL-514 reports reduced Dercum lipoma pain in Phase 2.** Sponsor topline announcement. [Localized fat removal](../topics/06_localized_fat.md#programs-and-next-milestones).
- **2026-09-21 — First obicetrapib approvals announced in Europe.** Regulatory action announced by sponsor. [Broad cardiovascular prevention, lipid therapies and screening](../topics/07_cardiovascular.md#programs-and-next-milestones).
- **2026-09-21 — Novo plans first human study of a PCSK9/GLP-1 combination.** Sponsor forecast of planned human trial. [Broad cardiovascular prevention, lipid therapies and screening](../topics/07_cardiovascular.md#programs-and-next-milestones).
- **2026-09-21 — New liver-development plans target MASH and alcohol-related disease.** Sponsor development forecast. [Liver disease, fibrosis and noninvasive assessment](../topics/13_liver.md#programs-and-next-milestones).
- **2026-09-21 — Lumateperone phase 3 mania results now available, including safety detail.** Sponsor conference poster and release; randomized phase 3, not yet a full peer-reviewed report. [Mental-health treatments, SSRIs and newer antidepressants](../topics/10_ssri_antidepressants.md#programs-and-next-milestones).
- **2026-09-21 — Bipolar II psilocybin pilot reports improvement and psychiatric adverse events.** Peer-reviewed open-label, single-arm pilot. [Psilocybin and related investigational therapies](../topics/09_psychedelics.md#programs-and-next-milestones).
- **2026-09-21 — Bempikibart off-treatment alopecia-areata results scheduled for September 30.** sponsor presentation announcement; older topline context separately labeled. [Hair loss and hair restoration](../topics/19_hair_loss.md#programs-and-next-milestones).
- **2026-09-21 — Nanovesicle and microneedle scar protocol reaches a small human pilot.** peer-reviewed prospective uncontrolled human study; original abstract appraised. [Scar prevention, treatment and stretch marks](../topics/21_scars.md#programs-and-next-milestones).
- **2026-09-19 — Small depression neurofeedback trial finds brief mood improvement, misses neural primary endpoint.** Peer-reviewed sham-controlled proof-of-principle study. [Mental-health treatments, SSRIs and newer antidepressants](../topics/10_ssri_antidepressants.md#programs-and-next-milestones).
- **2026-09-18 — Klygefa receives a positive European committee opinion for myasthenia gravis.** Regulator recommendation; opinion September 17, published September 18. [Autoimmune disease modification and immune-reset therapies](../topics/15_autoimmune.md#programs-and-next-milestones).
- **2026-09-17 — New Paliroden trial targets speech-in-noise difficulty with chronic tinnitus.** New formal human trial registration; no results. [Hearing and vision preservation/restoration](../topics/18_hearing_vision.md#programs-and-next-milestones).
- **2026-09-16 — Optimi plans Canadian phase 3 MDMA-assisted PTSD study.** Sponsor announcement of planned human trial; authorization sponsor-reported. [Psilocybin and related investigational therapies](../topics/09_psychedelics.md#programs-and-next-milestones).
- **2026-09-15 — Acute-asthma rademikibart study misses its primary endpoint.** Sponsor topline; overlap-window finding. [Allergy and airway disease](../topics/26_allergy_airway.md#programs-and-next-milestones).
- **2026-09-15 — EASi-KIDNEY stopped after lack of expected clinical benefit.** Sponsor trial-discontinuation announcement. [Kidney preservation and earlier CKD detection](../topics/17_kidney.md#programs-and-next-milestones).
- **2026-09-15 — ORIGIN 3 reports kidney-function and progression benefit.** Sponsor topline announcement in SEC filing. [Kidney preservation and earlier CKD detection](../topics/17_kidney.md#programs-and-next-milestones).
- **2026-09-15 — IPL pilot finds no objective regimen advantage after multiplicity correction.** peer-reviewed randomized human pilot; abstract appraised. [Skin aging, laxity and regeneration](../topics/20_skin_aging.md#programs-and-next-milestones).
- **2026-09-15 — Wear-time sensors do not improve orthodontic treatment outcomes in a small trial.** peer-reviewed randomized controlled human trial; abstract and registry appraised. [Dental alignment, regeneration and repair](../topics/25_dental.md#programs-and-next-milestones).
- **2026-09-14 — Ebribafusp advances into a kidney-disease basket trial.** Sponsor first-patient-dosed announcement. [Kidney preservation and earlier CKD detection](../topics/17_kidney.md#programs-and-next-milestones).
- **2026-09-14 — Topical facial-volume pilot provides early imaging evidence with substantial limitations.** peer-reviewed human pilot plus separate laboratory experiments; full text appraised. [Facial volume restoration and contour](../topics/22_facial_volume.md#programs-and-next-milestones).
- **2026-09-11 — Alopecia-areata study favors twice-daily over once-daily deuruxolitinib.** peer-reviewed randomized phase 2 study; new publication of an older completed trial. [Hair loss and hair restoration](../topics/19_hair_loss.md#programs-and-next-milestones).
- **2026-09-11 — Customized brackets trade shorter observed treatment for more breakages.** peer-reviewed retrospective comparative cohort; original abstract appraised. [Dental alignment, regeneration and repair](../topics/25_dental.md#programs-and-next-milestones).
- **2026-09-10 — Optimi plans Canadian phase 2 naturally derived psilocybin study.** Sponsor announcement of planned human trial; authorization sponsor-reported. [Psilocybin and related investigational therapies](../topics/09_psychedelics.md#programs-and-next-milestones).
- **2026-09-10 — Scar needling improves selected mechanical measures, without demonstrated pain benefit.** peer-reviewed randomized human study; abstract appraised. [Scar prevention, treatment and stretch marks](../topics/21_scars.md#programs-and-next-milestones).
- **2026-09-09 — p-tau217 plus APOE refines cognitive-risk estimates in pooled cohorts.** Peer-reviewed pooled prospective human cohorts; prognostic model/association. [Alzheimer's screening and therapies](../topics/08_alzheimers.md#programs-and-next-milestones).
- **2026-09-09 — Vornorexant long-term insomnia study published.** Peer-reviewed randomized-dose, open-label study; new publication of established program. [Sleep therapies and sleep disorders](../topics/12_sleep.md#programs-and-next-milestones).
- **2026-09-09 — Female-pattern hair-loss combination trial newly registered.** trial-registry entry; retrospectively registered study. [Hair loss and hair restoration](../topics/19_hair_loss.md#programs-and-next-milestones).
- **2026-09-09 — Stem-cell adjunct does not establish added orthodontic benefit in a small pilot.** peer-reviewed nonrandomized prospective human pilot; abstract appraised. [Dental alignment, regeneration and repair](../topics/25_dental.md#programs-and-next-milestones).
- **2026-09-07 — Rentosertib trial samples show proteomic aging-clock changes.** Peer-reviewed secondary human biomarker analysis. [Longevity and healthspan drug trials](../topics/05_longevity.md#programs-and-next-milestones).
- **2026-09-07 — KT-939 completes a year-long cosmetic-ingredient safety study.** sponsor regulatory-exchange announcement; preliminary safety findings. [Pigmentation and uneven skin tone](../topics/23_pigmentation.md#programs-and-next-milestones).
- **2026-09-03 — Baseline addition: genetic-risk-guided type 1 diabetes screening study.** Trial-registry baseline; last updated September 8. [Genetic screening and risk prediction](../topics/28_genetic_screening.md#programs-and-next-milestones).
- **2026-09-01 — Recovered baseline: biopsy PGT-A cohort separates whole-chromosome from segmental aneuploid transfer outcomes.** Recovered baseline; peer-reviewed retrospective multicenter cohort; original abstract appraised. [Genetic screening and risk prediction](../topics/28_genetic_screening.md#programs-and-next-milestones).
- **2026-08-31 — SPINOZA is formally registered to test obicetrapib in preclinical Alzheimer disease.** Recovered baseline: phase 2b registry, no efficacy result. [Alzheimer's screening and therapies](../topics/08_alzheimers.md#programs-and-next-milestones).
- **2026-08-19 — PrecivityAD2 FDA clearance recovered in baseline audit.** Recovered baseline: original FDA 510(k) clearance. [Alzheimer's screening and therapies](../topics/08_alzheimers.md#programs-and-next-milestones).
- **2026-04-01 — Baseline clarification: NVD003 pediatric bone-healing phase 3 trial.** Older trial-registry record rechecked; not new trial initiation. [Bone health, joint preservation and cartilage repair](../topics/11_joint_preservation.md#programs-and-next-milestones).

## Coverage and remaining gaps

### Whole-body MRI

**Status: focused, partial.** Refreshed HERCULES original registry, searched September human screening-outcome reports and upcoming trials; no new outcome verified in reviewed sources.

**Gaps:** HERCULES retains April 2025 verification and no results; actual ongoing recruitment unverified. Cochrane item is an August review protocol, not outcome evidence. Full repeat-screening literature and all screening cohorts not reappraised.

**Informal sources:** Flex Diet episode405 September21 show notes and timestamp list checked; educational discussion, no new trial result or concrete new rumor. Full audio not reviewed. https://podcasts.apple.com/nz/podcast/episode-405-whole-body-mri-ct-scans-and-what-imaging/id1488376804?i=1000790902903

**Sources checked:** [Source 1](https://clinicaltrials.gov/study/NCT06212479); [Source 2](https://pmc.ncbi.nlm.nih.gov/articles/PMC13504611/).

### Galleri and organ-specific cancer screening

**Status: focused, partial.** Read FDA meeting, exact voting/discussion questions, revised-assay performance and workup safety sections; discovered September22 repeat-round performance paper. Prior missing briefing gap materially closed.

**Gaps:** Full sponsor briefing, all FDA subgroup appendices, organ-specific screening interval outcomes and mortality publications not fully reappraised. Meeting has not occurred at check.

**Informal sources:** September21 Reddit market commentary calls briefing favorable; that inference is not an FDA endorsement. Automated secondhand CEO timing attribution lacked an original source and was not promoted. https://www.reddit.com/r/Wiseek/comments/1wmi37e/gral_fda_briefing_doc_backs_galleri_cancer_test/

**Sources checked:** [Source 1](https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-23-2026-molecular-and-clinical-genetics-panel-medical-devices-advisory-committee-meeting); [Source 2](https://www.fda.gov/media/194909/download); [Source 3](https://www.fda.gov/media/194908/download); [Source 4](https://www.fda.gov/media/194907/download); [Source 5](https://www.nature.com/articles/s41591-026-04652-8); [Source 6](https://www.nature.com/articles/s41591-026-04652-8/tables/2); [Source 7](https://www.nature.com/articles/s41591-026-04618-w).

### Cancer treatment, vaccines and recurrence prevention

**Status: focused, partial.** New oncology program/results discovery; verified VNX101 release and registry, intismeran ESMO schedule; original event dates retained.

**Gaps:** Full WCLC/PAPILLON/COPERNICUS tables, all ADC/radiopharmaceutical programs and new oncology labels not systematically reappraised. VNX101 detailed safety grades unavailable.

**Informal sources:** ModernaStock repost merely repeats original ESMO notice; SELLAS investor discussion/speculation did not establish new data or a confirmed REGAL readout date. https://www.reddit.com/r/ModernaStock/comments/1wme0iz/moderna_announces_latebreaking_data_to_be/

**Sources checked:** [Source 1](https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/moderna-announces-late-breaking-data-to-be-presented-at-esmo-congress-1224628); [Source 2](https://www.globenewswire.com/news-release/2026/09/21/3365351/0/en/vironexis-announces-complete-and-durable-responses-in-relapsed-refractory-all-patients-treated-with-vnx-101.html); [Source 3](https://clinicaltrials.gov/study/NCT06533579).

### Autoimmune disease modification and immune-reset therapies

**Status: focused, partial.** Verified EMA gefurulimab opinion; sought rap-cel/zola-cel restart, in-vivo programs and informal investigator planning.

**Gaps:** No verified rap-cel/zola-cel autoimmune restart. Full in-vivo CD19 September2 NEJM letter and all trial registries not reappraised.

**Informal sources:** OncLive September22 institutional planning signal recorded separately. BioCentury episode388 September21 and Can Do MS episode207 September9 surfaced, but full recordings not reviewed. https://biocentury.buzzsprout.com/1035190/episodes/19842477-ep-388-biotech-ipos-car-t-safety-pharma-tariffs

**Sources checked:** [Source 1](https://www.ema.europa.eu/en/medicines/human/EPAR/klygefa); [Source 2](https://www.dgrh.de/pressemitteilung/neue-immuntherapien-eroeffnen-perspektiven/).

### Allergy and airway disease

**Status: focused, partial.** Recovered September15 rademikibart primary-endpoint miss; verified original registry and VIASKIN filing forecast.

**Gaps:** Rademikibart exploratory-subgroup full paper inaccessible; all ERS abstracts/environmental-allergy studies not fully reviewed. No original COPD topline or actual VIASKIN BLA submission verified.

**Informal sources:** September8 Reddit discussion anticipated September readouts and correctly distinguished FEV1 from primary treatment failure; later actual result recorded separately, not rumor confirmation of efficacy. Bio Report190 Sept2 describes preclinical allergy CAR-T work, no verified human trial. https://www.reddit.com/r/biotech_stocks/comments/1waqxwm/cntb_has_two_phase_2_results_coming_this_month/

**Sources checked:** [Source 1](https://clinicaltrials.gov/study/NCT06940141); [Source 2](https://www.sec.gov/Archives/edgar/data/1613780/000162828026048453/dbvt-20260630.htm); [Source 3](https://onlinelibrary.wiley.com/doi/10.1111/all.70506); [Source 4](https://rss.globenewswire.com/news-release/2026/09/15/3361907/0/en/connect-biopharma-announces-positive-preliminary-topline-data-from-its-global-phase-2-study-of-rademikibart-as-an-add-on-treatment-for-acute-exacerbations-in-adult-and-adolescent-p.html).

### Infectious-disease prevention and treatment

**Status: focused, partial.** Verified ARIKAYCE priority-review action and searched human antibiotic/phage/new-class/vaccine/antiviral developments.

**Gaps:** Full ENCORE numerical tables and broad human antibiotic/antiviral registries not comprehensively refreshed; phage-antibiotic laboratory work excluded. Actual Utebzi launch not independently verified.

**Informal sources:** Targeted phage/antibiotic Reddit and podcast searches did not supply a usable new human-stage rumor; indexed search is incomplete, not proof no signal exists.

**Sources checked:** [Source 1](https://investor.insmed.com/2026-09-21-FDA-Grants-Priority-Review-to-Insmeds-sNDA-for-ARIKAYCE-R-amikacin-liposome-inhalation-suspension-for-Treatment-of-MAC-Lung-Disease-With-PDUFA-Target-Action-Date-Set-for-January-28%2C-2027).

### Genetic screening and risk prediction

**Status: focused, partial.** Verified new-to-watch T1D polygenic-risk screening registration; searched PRS/PGT/newborn/PGx research and deduplicated September 8 non-invasive PGT-A trial.

**Gaps:** Full SPLENDID/newborn/PGx/cascade-testing inventory remains partial. The PGT-A cohort abstract was appraised; full-paper methods, adjusted comparisons and long-term offspring follow-up remain unreviewed. No generic embryo-safety claim is inferred.

**Informal sources:** September 18 IVF discussion linked primary PGT-A research; avoid adopting commenters’ generalized efficacy claims or treating clinic anecdotes as trials. https://www.reddit.com/r/IVF/comments/1wk6bz5/new_study_17_lbr_for_segmental_aneuploid_embryos/

**Sources checked:** [Source 1](https://clinicaltrials.gov/study/NCT07802496); [Source 2](https://www.nature.com/articles/s41467-026-77628-4); [Source 3](https://pubmed.ncbi.nlm.nih.gov/42679947/); [Source 4](https://doi.org/10.1016/j.fertnstert.2026.08.1124); [Source 5](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:42679947&format=json&resultType=core).

### Bone health, joint preservation and cartilage repair

**Status: focused, partial.** Refreshed NVD003 original pivotal registry and searched EB613/lorecivivint/cartilage and fracture outcomes.

**Gaps:** No actual lorecivivint submission or new EB613 start verified. Full10-person engineered-cell paper and pamidronate low-back-pain paper remain unappraised; no negative or positive conclusion added from headlines.

**Informal sources:** Reddit osteoporosis engineered-cell discussion repeats existing September15 report; no new verified start or durable-outcome rumor found. https://www.reddit.com/r/science/comments/1whfv3z/a_living_medicine_made_from_genetically/

**Sources checked:** [Source 1](https://clinicaltrials.gov/study/NCT07112443); [Source 2](https://novadip.com/category/press-releases/).

### Non-opioid acute and chronic pain therapies

**Status: focused, partial.** Refreshed newly noticed suzetrigine pelvic-surgery protocol; searched chronic/neuropathic non-opioid developments, with CagriSema neuropathy and CBL514 Dercum results cross-linked from metabolic review.

**Gaps:** Pelvic-surgery trial is older May registration, not yet recruiting; November1 start/July2027 primary completion remain estimates. Full PAINWeek Mohs tables, VX993/Tonmya and all new mechanisms not fully reviewed.

**Informal sources:** September21 CRPS Journavx discussion is individual off-label experience, not a new trial or reliable efficacy rumor. https://www.reddit.com/r/CRPS/comments/1wlyinj/journavx/

**Sources checked:** [Source 1](https://clinicaltrials.gov/study/NCT07600697); [Source 2](https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/capital-markets-day/2026/Diabetes-presentation.pdf); [Source 3](https://clinicaltrials.gov/study/NCT06797869).

### GLP-1 and related metabolic therapies

**Status: focused, partial.** September 5–22 overlap; Viking maintenance, Novo CMD/readouts, EASD timing, human-development announcements and fresh registries. Priority September 18–22.

**Gaps:** Full tables/CIs and treatment-policy estimands for new CagriSema trials unavailable. VK2735-102 NCT identifier not matched; exact registry phase not asserted. Not a complete global registry/conference census; no full webcast audio review.

**Informal sources:** Targeted Reddit and management-talk searches; today's VK2735 discussion mainly repeats the official release. Novo investor posts do not establish unpublished readouts. CagriSema neuropathy cross-reported once in pain.

**Sources checked:** [Source 1](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens); [Source 2](https://www.globenewswire.com/de/news-release/2026/09/21/3365319/0/en/novo-s-cagrisema-delivers-superior-weight-loss-versus-tirzepatide-in-reimagine-5-trial.html); [Source 3](https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/capital-markets-day/2026/Diabetes-presentation.pdf); [Source 4](https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/capital-markets-day/2026/obesity-presentation-cmd-2026.pdf); [Source 5](https://clinicaltrials.gov/study/NCT06534411); [Source 6](https://clinicaltrials.gov/study/NCT06388187); [Source 7](https://clinicaltrials.gov/study/NCT06797869).

### Muscle building and preservation

**Status: focused, partial.** Rechecked bimagrumab/tirzepatide, COURAGE, PLATEAU and SRK forecasts; found a separate historical Columbia bimagrumab study. Distinguished registry changes from mirror-refresh dates.

**Gaps:** Lilly bimagrumab/tirzepatide Phase 2 has no posted results; full release-date search and functional endpoints remain incomplete. COURAGE registry total actual enrollment 1005 differs from the 599 initial readout cohort; do not conflate. Original Cantor webcast audio not reviewed; third-party transcript only. Sarcopenia/disease-specific pipeline census incomplete.

**Informal sources:** Read September 9 Investing.com transcript of Veru Cantor discussion; captured explicitly informal Phase 3 scale/functional-endpoint direction. Reddit queries mostly returned gray-market questions or prior data, excluded. Existing PLATEAU Q1 2027 interim forecast repeated, not re-alerted.

**Sources checked:** [Source 1](https://clinicaltrials.gov/study/NCT06643728); [Source 2](https://clinicaltrials.gov/study/NCT06901349); [Source 3](https://clinicaltrials.gov/study/NCT06299098); [Source 4](https://clinicaltrials.gov/study/NCT07446998); [Source 5](https://clinicaltrials.gov/study/NCT05933499); [Source 6](https://www.investing.com/news/transcripts/veru-at-12th-annual-cantor-fitzgerald-global-healthcare-conference-muscle-focus-93CH-4894905).

### Longevity and healthspan drug trials

**Status: focused, partial.** TAME direct status, rentosertib September 7 proteomics paper, rapamycin RESTOR and AgelessRx pilot/APOE4 registry follow-up.

**Gaps:** TAME actual launch/registration remains unverified; official page still fundraises to launch. AgelessRx larger planned 186-person study registration not confirmed; old 30-person record has elapsed unrefreshed estimate. Rentosertib full parent-trial safety not separately reconstructed; proteomic changes are not healthspan outcomes. Senolytic/metformin worldwide registry census and complete podcasts not covered.

**Informal sources:** Targeted Reddit/rapamycin/podcast/TAME searches. Excluded animal-only items and unsupported TAME interim-result blog claims lacking a retrievable original study, conflicting with AFAR launch status. Did not treat search popularity/reposts as corroboration.

**Sources checked:** [Source 1](https://www.afar.org/tame-trial); [Source 2](https://www.nature.com/articles/s41587-026-03286-y); [Source 3](https://clinicaltrials.gov/study/NCT06658093); [Source 4](https://clinicaltrials.gov/study/NCT07475546); [Source 5](https://clinicaltrials.gov/study/NCT05938920).

### Localized fat removal

**Status: focused, partial.** CBL-514 Dercum original readout, SUPREME-01 current status, RZL-012/AYP-101/tesamorelin and cellulite registry/source discovery.

**Gaps:** Full Dercum arm denominators, CIs and safety table absent; larger-trial timing unknown. No independently verified new RZL-012 result or tesamorelin new-indication result; aesthetic device comparative census incomplete. September 30 visceral-fat presentation has not occurred within this check.

**Informal sources:** Targeted CBL-514/tesamorelin/cellulite Reddit and talk searches mainly returned personal experience, gray-market sourcing and promotion; excluded. Sponsor lipedema feasibility statement remains a plan, not an active trial.

**Sources checked:** [Source 1](https://www.caliwaybiopharma.com/en/news-detail/CBL-514-CBL-0202DD-Phase2-met-primary-endpoint-ENG/); [Source 2](https://clinicaltrials.gov/study/NCT06303570); [Source 3](https://clinicaltrials.gov/study/NCT07140939); [Source 4](https://clinicaltrials.gov/study/NCT06256445); [Source 5](https://clinicaltrials.gov/study/NCT03375788).

### Broad cardiovascular prevention, lipid therapies and screening

**Status: focused, partial.** EU obicetrapib announcement/EMA opinions; Novo oral PCSK9/GLP-1 plan; VERVE-102, Lp(a) outcome registries, new lipid entrants and ARO-DIMER target correction. Cross-topic ZEUS/EASi gaps.

**Gaps:** Formal European Commission decision and updated final obicetrapib SmPC not retrieved; authorization is sponsor-announced. PREVAIL old completion estimate is not a confirmed readout schedule; no new results. VERVE Phase 2 initiation and full ASCVD screening/CAC/CCTA/AI-plaque census incomplete. MWX203 precise target mechanism not verified, so not assigned from biomarker lists.

**Informal sources:** Obicetrapib approval lead corroborated by original sponsor. Existing Attia/Davidson Alzheimer's-prevention hypothesis has no newly verified clinical outcome; root/Alzheimer's topic owns unchanged rumor. Investor posts and republished ZEUS news not counted as new findings.

**Sources checked:** [Source 1](https://www.menarini.com/en-us/news/news-detail/menarini-group-and-newamsterdam-pharma-receive-european-commission-approval-for-ubeslo-obicetrapib-monotherapy-and-evlarco-obicetrapib-plus-ezetimibe-fixed-dose-combination.html); [Source 2](https://www.ema.europa.eu/en/medicines/human/EPAR/ubeslo); [Source 3](https://www.ema.europa.eu/en/medicines/human/EPAR/evlarco); [Source 4](https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/capital-markets-day/2026/CVD-liver-presentation.pdf); [Source 5](https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-announces-interim-topline-clinical); [Source 6](https://clinicaltrials.gov/study/NCT05202509); [Source 7](https://clinicaltrials.gov/study/NCT06164730); [Source 8](https://clinicaltrials.gov/study/NCT05581303); [Source 9](https://clinicaltrials.gov/study/NCT06292013); [Source 10](https://clinicaltrials.gov/study/NCT06112418); [Source 11](https://clinicaltrials.gov/study/NCT07803822); [Source 12](https://clinicaltrials.gov/study/NCT07619131); [Source 13](https://www.boehringer-ingelheim.com/human-health/boehringer-provides-update-easi-kidney-trial).

### Liver disease, fibrosis and noninvasive assessment

**Status: focused, partial.** Novo September 21 MASH/ALD plans, EMA September meeting, efruxifermin registry timing, TGM-312 registry-identifier recovery and ATHENA status gap.

**Gaps:** Wegovy September EU procedure outcome not explained in retrieved CHMP highlights; no approval/rejection inferred. ATHENA discontinuation lead not resolved by current primary record, which still predates alleged news. SYNCHRONY RW completion windows elapsed without posted result; no assumed readout. Noninvasive liver-test outcome/comparative census incomplete; no full CMD audio review.

**Informal sources:** Read September 18 original Reddit post noticing Wegovy's absence from meeting highlights; verified agenda/absence and retained outcome uncertainty. New CMD liver plans are sourced to official slides, not Reddit interpretation.

**Sources checked:** [Source 1](https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/capital-markets-day/2026/CVD-liver-presentation.pdf); [Source 2](https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-14-17-september-2026_en.pdf); [Source 3](https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2026); [Source 4](https://www.reddit.com/r/NovoNordisk_Stock/comments/1wjxoxg/wegovys_mash_indication_was_for_adoption_at_chmp/); [Source 5](https://clinicaltrials.gov/study/NCT06215716); [Source 6](https://clinicaltrials.gov/study/NCT06161571); [Source 7](https://clinicaltrials.gov/study/NCT06528314); [Source 8](https://clinicaltrials.gov/study/NCT07427680); [Source 9](https://clinicaltrials.gov/study/NCT06200207).

### Kidney preservation and earlier CKD detection

**Status: focused, partial.** Recovered September 15 EASi-KIDNEY negative development and ORIGIN 3 final readout, September 14 ebribafusp first-dose announcement; finerenone/new kidney trial registries and BEAT-PKD gap.

**Gaps:** Detailed final ORIGIN 3 arm-level safety/estimand/composite definitions need congress/publication; FDA full-approval action not yet occurred. EASi-KIDNEY registry remains active/not recruiting while sponsor announced stopping; status is administrative, not proof that decision reversed. BEAT-PKD estimated September 21 start elapsed while registry says not yet recruiting; actual dosing not verified. Kidney early-detection and global disease-specific census incomplete; full audio sources not reviewed.

**Informal sources:** Read Reddit kidney/ADPKD/lupus trial discussions: self-identified VX-407 participant's mixed cyst-diameter anecdotes do not establish trial efficacy; trial-intake and transplant posts are leads, not outcome announcements. Primary sponsor/registry evidence used for included findings.

**Sources checked:** [Source 1](https://www.boehringer-ingelheim.com/human-health/boehringer-provides-update-easi-kidney-trial); [Source 2](https://www.sec.gov/Archives/edgar/data/1831828/000119312526391280/d32300dex991.htm); [Source 3](https://www.sec.gov/Archives/edgar/data/1831828/000119312526391280/d32300d8k.htm); [Source 4](https://www.globenewswire.com/news-release/2026/09/14/3361045/37519/en/akebia-therapeutics-announces-first-patient-dosed-in-phase-2-basket-trial-of-ebribafusp-in-rare-complement-mediated-kidney-diseases.html); [Source 5](https://clinicaltrials.gov/study/NCT06531824); [Source 6](https://clinicaltrials.gov/study/NCT04716231); [Source 7](https://clinicaltrials.gov/study/NCT06419205); [Source 8](https://clinicaltrials.gov/study/NCT07282821); [Source 9](https://clinicaltrials.gov/study/NCT07223502).

### Alzheimer's screening and therapies

**Status: focused, partial.** Read full topic, baseline/state and September18 gaps; September5–22 treatment, blood-test, human prevention, safety/negative searches. Verified SPINOZA original registry and FDA PrecivityAD2 clearance, appraised p-tau217/APOE original abstract and investigator discussion. Revisited Attia/Davidson original notes. Earlier ALZ101, PrevenTRON and tau-platform entries deduplicated.

**Gaps:** Exact ALZ101 phase2 and PrevenTRON registry matching remains unresolved. All current anti-amyloid labels/recall-database changes and older lithium/XPro/external-counterpulsation full papers were not comprehensively appraised. SPINOZA registration is verified but actual enrollment/start is not; September estimate is not confirmation. Full p-tau217/APOE paper not accessed; original abstract used. Grifols forthcoming November RWE presentation identified, without new numerical results to appraise.

**Informal sources:** Rechecked the original September14 Attia/Davidson episode chapter notes; registered-study existence now verified independently, preventive benefit remains a hypothesis. Targeted recent Reddit Alzheimer/biomarker queries mostly personal anecdotes or reposts; no separate new verified efficacy rumor extracted. Full podcast/transcript sweep remains incomplete.

**Sources checked:** [Source 1](https://clinicaltrials.gov/study/NCT07794670); [Source 2](https://doi.org/10.1016/S1474-4422(26)00313-3); [Source 3](https://pubmed.ncbi.nlm.nih.gov/42716078/); [Source 4](https://www.accessdata.fda.gov/cdrh_docs/pdf25/K253240.pdf); [Source 5](https://peterattiamd.com/michaeldavidson/); [Source 6](https://www.grifols.com/en/view-news/-/news/grifols-strengthens-evidence-supporting-the-ambar-program-in-alzheimer-s-disease-with-real-world-evidence-data); [Source 7](https://www.cuimc.columbia.edu/news/blood-and-gene-test-combo-forecasts-alzheimers-symptoms-years-onset); [Source 8](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K253240).

### Psilocybin and related investigational therapies

**Status: focused, partial.** Read full topic and prior gaps; September5–22 human-stage, safety and regulatory searches. Appraised bipolar-II pilot, Optimi original phase2/3 planned-trial releases, FDA hearing page and original MDMA report/MAPS response. Previously reported Panorama, COMP005 and personality-disorder subgroup deduplicated. Checked L-130 lead against older 2023 study/2024 publication context.

**Gaps:** FDA September14 full proceedings/transcript still not appraised. Official page checked; October5 comment deadline retained. No new binding policy/product approval inferred. Definium actual Psych Congress files and new analyses, GH001 phase3 registration and complete Helus/BPL003 status sweep remain gaps. Optimi registry IDs and design details not matched. L-130 planned September16 presentation not obtained; older ten-person phase1a results must not be relabeled new September efficacy. U.S. MDMA filing acceptance, decision date and approval remain unverified.

**Informal sources:** Existing anonymous-source Resilient report and MAPS original response rechecked: MAPS expressly responds to reported refiling and says it has no active role in Resilient development. Reposts are not independent confirmation. September18 Alaina Jaster hearing commentary appraised as participant/observer interpretation, not FDA policy; no new approval-date rumor promoted. Original talk/podcast coverage remains selective.

**Sources checked:** [Source 1](https://www.psychiatrist.com/jcp/open-label-dose-escalation-psilocybin-assisted-therapy-bipolar-ii-depression/); [Source 2](https://clinicaltrials.gov/study/NCT05065294); [Source 3](https://ir.optimi.net/press-releases/2026-09-expands-clinical-program-with-phase-3-trial-evaluating-mdma-assisted); [Source 4](https://ir.optimi.net/press-releases/2026-09-to-initiate-phase-2-clinical-trial-evaluating-psilocybin-assisted); [Source 5](https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/considerations-potential-future-therapeutic-use-psychedelic-drugs-public-hearing-09142026); [Source 6](https://psychedelicalpha.com/news/two-years-after-rejection-resilient-quietly-refiles-mdma-for-ptsd-application/); [Source 7](https://maps.org/2026/08/10/maps-responds-to-report-of-progress-for-mdma-assisted-therapy-for-ptsd-with-fda/); [Source 8](https://psychedelicamericas.org/news/whos-in-the-room-and-who-decides-open-questions-following-the-fda-hearing-on-psy).

### Mental-health treatments, SSRIs and newer antidepressants

**Status: focused, partial.** Read full topic and September18 gaps; searched MDD/anxiety/OCD/PTSD/bipolar/addiction human results, safety and new programs through September22. Closed numerical lumateperone mania gap with original poster/release and registry; appraised the small VTA neurofeedback trial and cross-linked bipolar-II psilocybin/Optimi programs. Prior PIPE307 negative result and emotional-blunting/KetSet registrations deduplicated.

**Gaps:** No distinct new 2026 seltorexant numerical randomized result verified: J&J 2026 index exposes burden/management observational posters; the easily found MDD3005 comparison is dated September22,2025. Do not relabel it 2026. Liafensine phase3 and ansofaxine U.S. development not fully refreshed; all OCD/PTSD/addiction programs not exhaustively checked. Older Ket-BD/RECOVER and OCD epigenetic full-text appraisal remain incomplete. VTA neurofeedback detailed adverse-event analysis not located.

**Informal sources:** Targeted Reddit seltorexant/mental-health searches found anecdotes and gray-market discussion (excluded), without a distinct source-grounded new program rumor. Original clinician talk/podcast sweep incomplete.

**Sources checked:** [Source 1](https://www.jnj.com/media-center/press-releases/caplyta-lumateperone-shows-significant-and-rapid-improvement-in-bipolar-mania-in-pivotal-phase-3-study); [Source 2](https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2026/psych-congress/lumateperone-treatment-of-manic-episodes-with-or-without-mixed-features-in-bipol.pdf); [Source 3](https://clinicaltrials.gov/study/NCT06462586); [Source 4](https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/psych-congress-2026); [Source 5](https://www.nature.com/articles/s41380-026-03911-x); [Source 6](https://clinicaltrials.gov/study/NCT07393919); [Source 7](https://www.jnj.com/innovativemedicine/us/news-center/neuroscience/johnson-johnsons-investigational-seltorexant-shows-numerically-higher-response-in-patients-with-depression-with-insomnia-symptoms-with-fewer-side-effects-compared-to-quetiapine-xr); [Source 8](https://clinicaltrials.gov/study/NCT04138680).

### Sleep therapies and sleep disorders

**Status: focused, partial.** Read full topic and Sep18/Sep19 updates. Verified new vornorexant publication/Japan approval context; rechecked Orzeyful official pending-availability language, FDA label and Federal Register API for scheduling; inspected current original Brilliance3/Vibrance3/Neuro-DORA registry records. Targeted insomnia, OSA, hypersomnolence, circadian and RLS searches.

**Gaps:** Federal Register exact-name API searches returned no oveporexton/Orzeyful records; this is a negative search, not proof that no regulatory action exists. November launch remains sponsor forecast pending DEA. Exact vornorexant long-term trial registry/full safety tables not matched. Daridorexant daytime-function study registry/start and tasimelteon hearing outcome remain unresolved. Complete CBT-I/digital/circadian/RLS registry refresh and RLS conference late-breakers incomplete. Wearable insomnia meta-analysis identified as secondary synthesis, not a new drug trial; no new primary-result claim promoted.

**Informal sources:** Recent Reddit Orzeyful threads mostly repeat pending launch, access concerns and individual experiences; no independently supported new launch/scheduling rumor extracted. Seltorexant gray-market material excluded. Original podcast sweep incomplete.

**Sources checked:** [Source 1](https://pubmed.ncbi.nlm.nih.gov/42731338/); [Source 2](https://doi.org/10.1016/j.sleep.2026.109260); [Source 3](https://www.taisho.co.jp/company/news/2025/20250901001954/); [Source 4](https://www.orzeyful.com/); [Source 5](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220860Orig1s000lbl.pdf); [Source 6](https://www.federalregister.gov/api/v1/documents.json?conditions%5Bterm%5D=oveporexton&per_page=20&order=newest); [Source 7](https://clinicaltrials.gov/study/NCT07455383); [Source 8](https://clinicaltrials.gov/study/NCT07502443); [Source 9](https://clinicaltrials.gov/study/NCT07540897); [Source 10](https://clinicaltrials.gov/study/NCT06843590); [Source 11](https://clinicaltrials.gov/study/NCT06823752); [Source 12](https://pubmed.ncbi.nlm.nih.gov/42727109/); [Source 13](https://www.pmda.go.jp/files/000279952.pdf).

### Hearing and vision preservation/restoration

**Status: focused, partial.** Read topic and prior gaps; searched inherited/acquired hearing and vision programs, safety/negative studies and entrants through September22. Verified Paliroden REACT registration; rechecked original AC102, Rincell, PST611 and BIRD1 records. Reviewed older terminated Roche geographic-atrophy and Regeneron uveitis entries as baseline leads, not new September terminations. BGE102/BEST1/PST611 prior events deduplicated.

**Gaps:** PRIMA/Otarmeni latest labels, regulator safety and commercial availability not comprehensively refreshed. SENS601 August31 authorization/Annexon ARCHERII original older leads and ACHIEVE secondary biomarker full paper still need appraisal. AC102 original record remains January16 snapshot with elapsed July31 completion estimate, not confirmation of phase3/tinnitus plans. PST611 registry enrolled8 vs sponsor treated6 remains a denominator clarification. Recovered RO7669330 GA termination (last posted Aug10: dose-limiting AEs reached stopping criteria) and REGN7041 TITAN uveitis termination (Aug17: unfavorable benefit-risk) are older baseline leads without AE details; consider future baseline additions, not this week’s alerts.

**Informal sources:** Original Aug29 AC102 secondhand-email thread revisited; no official confirmation of phase3/tinnitus 2027 claim located. September18 Paliroden Reddit lead traced to original registry and promoted as formal registration, not rumor. Additional informal searches were selective.

**Sources checked:** [Source 1](https://clinicaltrials.gov/study/NCT07826507); [Source 2](https://clinicaltrials.gov/study/NCT05776459); [Source 3](https://clinicaltrials.gov/study/NCT07032038); [Source 4](https://clinicaltrials.gov/study/NCT06996730); [Source 5](https://clinicaltrials.gov/study/NCT06961370); [Source 6](https://clinicaltrials.gov/study/NCT07218770); [Source 7](https://www.reddit.com/r/tinnitusresearch/comments/1w1vebv/audiocure_ac102_update/); [Source 8](https://www.reddit.com/r/tinnitusresearch/comments/1wjrk0j/a_study_testing_safety_and_efficacy_of/).

### Hair loss and hair restoration

**Status: focused, partial.** Read full current topic, including September 19 mechanism-primer changes; searched September 5–22 original papers, sponsor releases, registries, new programs, alopecia areata and biological graying. Refreshed AWAKEN/HEADLINE and new KeraFactor/Revian records. Added Q32 presentation timing and appraised a new publication of an older deuruxolitinib dosing trial. PP405 still not yet recruiting; existing forecasts were not re-alerted.

**Gaps:** Kintor original HKEX index and March/September filings found; the August interim PDF failed in browser text, and a matched Chinese pivotal registry remains unresolved. No new GT20029 late-stage start verified. Deuruxolitinib full paper not appraised; registry already had results from the older trial, so publication must not be treated as fresh trial completion. A September 15 maresin-1 canities/vitiligo mechanism paper used human profiling but intervention experiments in mice and cells; excluded as human-treatment news. BioQ candidate-specific registry and dated human results remain unverified. No comprehensive updated alopecia-areata regulatory safety-label inventory or full investor-call transcript review.

**Informal sources:** Targeted Reddit/podcast/talk searches included PP405 registration discussion and ABS-201 investor speculation. Funding and registry estimates do not establish efficacy or first dosing. Original clascoterone and BQ-002 timing posts plus sponsor text rechecked; both remain unconfirmed with no repeat alert.

**Sources checked:** [Source 1](https://clinicaltrials.gov/study/NCT07819435); [Source 2](https://clinicaltrials.gov/study/NCT07317544); [Source 3](https://clinicaltrials.gov/study/NCT07810504); [Source 4](https://clinicaltrials.gov/study/NCT06018428); [Source 5](https://clinicaltrials.gov/study/NCT03811912); [Source 6](https://pubmed.ncbi.nlm.nih.gov/42727780/); [Source 7](https://pelagepharma.com/press-releases/); [Source 8](https://ir.veradermics.com/); [Source 9](https://investors.absci.com/); [Source 10](https://www.cosmohealthconfidence.com/news/64300770-h1-2026); [Source 11](https://www.bioq.com/); [Source 12](https://ir.q32bio.com/news-releases/news-release-details/q32-bio-announces-upcoming-late-breaking-presentation-results); [Source 13](https://ir.q32bio.com/news-releases/news-release-details/q32-bio-announces-positive-36-week-topline-results-part-b-signal); [Source 14](https://doi.org/10.1016/j.jaad.2026.09.013).

### Skin aging, laxity and regeneration

**Status: focused, partial.** Searched September 5–22 human rejuvenation, laxity, topical, energy-device and safety papers; appraised the randomized IPL pilot. Refreshed KB304 registry, which still has stale 2025 estimates, and searched sponsor updates. September 17 Allergan small skin-care studies already recorded and deduplicated.

**Gaps:** September 22 multimodal RF/microneedle-RF/muscle-stimulation trial abstract lacks sample size and numerical effects; full paper not appraised, so no efficacy alert promoted. Allergan September 17–20 conference window has elapsed; no full poster/safety tables recovered. This does not prove presentation or positive completion. FDA RF safety communication was not freshly appraised in this run; rare-harm surveillance remains incomplete.

**Informal sources:** Searched Reddit and podcasts. September 7 Skinside Out description discusses existing retinoids, devices and cosmetic products; no attributable new clinical-development prediction. Full audio/transcripts not reviewed. Old 2025 KB304 call remains superseded by already recorded August 2026 guidance.

**Sources checked:** [Source 1](https://pubmed.ncbi.nlm.nih.gov/42747114/); [Source 2](https://doi.org/10.3791/73264); [Source 3](https://pubmed.ncbi.nlm.nih.gov/42766316/); [Source 4](https://clinicaltrials.gov/study/NCT06724900); [Source 5](https://podcasts.apple.com/ca/podcast/optimize-your-upcoming-fall-treatments/id1790265036?i=1000788288833).

### Scar prevention, treatment and stretch marks

**Status: focused, partial.** Searched human scar prevention, established scars, keloids, stretch marks, new antifibrotic/vesicle programs and negative findings. Added randomized dry-needling result and preliminary nanovesicle combination pilot. Refreshed both verteporfin records and siRNA registry; searched Syntara updates.

**Gaps:** September 8 SPARC/IL4-RA siRNA full research letter remains inaccessible. No efficacy conclusion drawn. Verteporfin records remain not yet recruiting with stale estimates. Syntara Phase 1 scar-program identifiers and completion of Q3 recruitment remain unverified. Scar-needling full safety data and nanovesicle pilot full methods, numerical changes and registration remain gaps.

**Informal sources:** Targeted Reddit and podcast/talk searches found repeated August registry interpretations and self-experimentation/case anecdotes. No new specific formal-development rumor was selected. A search result containing a September 23 future-dated comment was excluded from this September 22 check.

**Sources checked:** [Source 1](https://pubmed.ncbi.nlm.nih.gov/42723368/); [Source 2](https://pubmed.ncbi.nlm.nih.gov/42765643/); [Source 3](https://clinicaltrials.gov/study/NCT06033430); [Source 4](https://clinicaltrials.gov/study/NCT06944249); [Source 5](https://clinicaltrials.gov/study/NCT07488988); [Source 6](https://clinicaltrials.gov/study/NCT06138964); [Source 7](https://doi.org/10.1093/bjd/ljag385); [Source 8](https://syntaratx.com.au/news/); [Source 9](https://www.reddit.com/r/verteporfin/comments/1vypnsk/verteporfin_status_upcoming_trials_and/); [Source 10](https://doi.org/10.1080/10669817.2026.2730521); [Source 11](https://doi.org/10.1039/D6BM01092J).

### Facial volume restoration and contour

**Status: focused, partial.** Searched new filler, fat-graft, biostimulator, volume-restoration and safety evidence. Retrieved and appraised full September 14 KPRE/Adipeau paper and original trial registry, keeping lab mechanisms separate from the uncontrolled 35-person human imaging study.

**Gaps:** KPRE paper has no usable adverse-event table and no randomized replication; prespecified elasticity was not measured. September 18 self-protecting HA filler work is preclinical; not promoted to a new human therapy. No comprehensive fresh worldwide FDA/device-clearance or delayed-filler-complication inventory. Earlier HA-collagen RCT reporting discrepancy remains unresolved.

**Informal sources:** Searched Reddit, podcasts and talks. September 15 Adam Lamb/Neal Deot episode description discusses facial fat grafting and GLP-1-associated changes without a new trial milestone. September 14 GLP-1 Hub/Brian Pilcher description located, but full page/transcript fetch failed. No quotation or unverified development date invented.

**Sources checked:** [Source 1](https://pmc.ncbi.nlm.nih.gov/articles/PMC13572798/); [Source 2](https://doi.org/10.34133/csbj.0213); [Source 3](https://clinicaltrials.gov/study/NCT04769193); [Source 4](https://pubmed.ncbi.nlm.nih.gov/42761992/); [Source 5](https://www.buzzsprout.com/2460130/episodes/19806256-the-business-of-plastic-surgery-building-a-practice-patients-trust); [Source 6](https://www.buzzsprout.com/2455627/episodes/19792263-ozempic-face-can-you-reverse-it-w-brian-pilcher-phd?t=0).

### Pigmentation and uneven skin tone

**Status: focused, partial.** Searched human melasma, PIH, solar spots and vitiligo papers; appraised new-to-notebook September 7 KT-939 safety announcement and September 22 Incyte EADV schedule. Refreshed STOP-V1/V2 records; no newly posted registry results. Prior melasma pilot/PRP findings deduplicated.

**Gaps:** September 19 ruxolitinib-versus-tacrolimus prospective paper and September 13 graft-versus-cell-suspension vitiligo report had no original abstracts; full results inaccessible and not inferred from titles. September 21 picosecond laser melasma abstract reviewed: retrospective 29 women, 12-week follow-up, no comparator. Full tables unavailable; minor series was not promoted. KT-939 disposition from 130 originally enrolled to 114 continuous users, complete adverse-event accounting and matched registry remain unresolved.

**Informal sources:** Reddit and podcast searches found personal tranexamic-acid/hydroquinone experiences and procedure discussions rather than a traceable new formal-program timing or efficacy rumor. No personal anecdote was recast as controlled evidence.

**Sources checked:** [Source 1](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0907/2026090700007.pdf); [Source 2](https://incytecorp.gcs-web.com/news-releases/news-release-details/incyte-data-european-academy-dermatology-and-venereology-eadv); [Source 3](https://clinicaltrials.gov/study/NCT06113445); [Source 4](https://clinicaltrials.gov/study/NCT06113471); [Source 5](https://pubmed.ncbi.nlm.nih.gov/42762996/); [Source 6](https://pubmed.ncbi.nlm.nih.gov/42732550/); [Source 7](https://pubmed.ncbi.nlm.nih.gov/42765845/).

### Acne and rosacea

**Status: focused, partial.** Searched original September 5–22 acne/rosacea papers, investigational vaccine, topical drugs, devices, safety and sponsor developments. Refreshed SP0268 and rosacea redness-study records; their recruiting statuses/dates remain unchanged. No new material efficacy or regulatory result was verified within this focused check.

**Gaps:** September 17 topical-ruxolitinib rosacea case series and September 11 spruce-extract exploratory report were located; full methods/safety not appraised and no indication-level efficacy conclusion made. An isotretinoin-study correction was indexed September 5; its material effect on results not resolved in this pass. No complete new worldwide device-clearance review or SP0268 investigator update beyond the registry.

**Informal sources:** Targeted Reddit, podcast and talk queries. September 17 Dr Mitch Shulman radio-podcast segment is general acne-versus-rosacea discussion; episode notes lack a trial claim and no audio transcript was reviewed. No new attributable SP0268 rumor selected.

**Sources checked:** [Source 1](https://clinicaltrials.gov/study/NCT06316297); [Source 2](https://clinicaltrials.gov/study/NCT07521462); [Source 3](https://pubmed.ncbi.nlm.nih.gov/42755388/); [Source 4](https://pubmed.ncbi.nlm.nih.gov/42725543/); [Source 5](https://pubmed.ncbi.nlm.nih.gov/42700362/); [Source 6](https://podfollow.com/the-andrew-carter-podcast/episode/09f493c42797bfe752ce2521ab7510f9a68a9d4e/view).

### Dental alignment, regeneration and repair

**Status: focused, partial.** Searched human aligner/braces materials, clinical outcomes, monitoring, acceleration, retention, root/gum health, regeneration and repair. Appraised negative wear-sensor RCT, LightForce comparative cohort and cell-adjunct orthodontic pilot. Rechecked printed-aligner and new self-ligating comparison registries, and Toregem primary news.

**Gaps:** The September 20 final-completion estimate for NCT07496892 has now elapsed; record still not yet recruiting, last updated March 27, and no results. Remove any implication that the study completed. Toregem jRCT Phase 1 original page again returned 403; Phase IIa dosing and a matched registry remain unverified. Sponsor news still ends with August leadership/trial-notification events. Wear-sensor paper versus registry enrollment discrepancy (58 versus 52) unresolved; full comparative papers and complete safety/root/retention outcomes not appraised. New Bangladesh university aligner-versus-braces study is listed ongoing September 2026–August 2027, but design details and matched registry remain unverified; not promoted as an efficacy event. NCT07638397 was posted earlier and remains not yet recruiting despite September 15 estimated start.

**Informal sources:** Targeted Reddit and podcast searches. September 14 Kliq This episode description repeats speculative tooth-regrowth-by-2030 discussion; no named new clinical source or verified transcript. Promotional aligner-speed posts and old generic tooth-regrowth forecasts were not repeated as new signals.

**Sources checked:** [Source 1](https://pubmed.ncbi.nlm.nih.gov/42744723/); [Source 2](https://clinicaltrials.gov/study/NCT05213338); [Source 3](https://pubmed.ncbi.nlm.nih.gov/42730520/); [Source 4](https://pubmed.ncbi.nlm.nih.gov/42736658/); [Source 5](https://clinicaltrials.gov/study/NCT07496892); [Source 6](https://clinicaltrials.gov/study/NCT07638397); [Source 7](https://toregem.co.jp/en/news); [Source 8](https://jrct.mhlw.go.jp/en-latest-detail/jRCT2051240154); [Source 9](https://di.bmu.ac.bd/research/57?source=irb); [Source 10](https://doi.org/10.1016/j.ejwf.2026.08.002); [Source 11](https://doi.org/10.2319/030326-188.1); [Source 12](https://doi.org/10.2174/011574888X485355260901075010).

## Corrections and unresolved informal claims

ARO-DIMER-PA targets **PCSK9/APOC3**; the older Latest preview incorrectly said ANGPTL3. Corrected the preview to match the original Arrowhead source and topic notes; this is an editorial correction, not a new trial result.

Existing clascoterone, BQ-002, AC102, Resilient and obicetrapib-benefit claims were revisited. No new efficacy or approval confirmation is inferred. SPINOZA registration closes a program-existence gap only. Veru’s possible enobosarm phase 3 design is an informal management statement, and Wegovy’s omitted CHMP mention leaves the MASH outcome unresolved; neither is an FDA or EMA commitment. The new OncLive IBD planning signal is attributed to an indexed discussion summary, with original-video access limitations explicit.

## Website edition

The notebook was verified before export. This update refreshes topic summaries, milestone previews, and affected charts; publication is tracked separately from research verification. The public edition excludes personal notes and identifying context.